Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01045668 · ClinicalTrials.gov registry record · Phase 3

Ablation of Clinical Ventricular Tachycardia Versus Addition of Substrate Ablation on the Long Term Success Rate of VT Ablation

A Phase 3 study of Ventricular Tachycardia, sponsored by Texas Cardiac Arrhythmia Research Foundation.

Completed
Registry status
Phase 3
Development phase
120
Enrollment target
1
Study location

NCT01045668 is a Phase 3 study of Ventricular Tachycardia that has completed, run by Texas Cardiac Arrhythmia Research Foundation. The registered enrollment target is 120 participants, below the 284-participant average among 28 other Ventricular Tachycardia trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01045668, a Phase 3 study of Ventricular Tachycardia, has completed, sponsored by Texas Cardiac Arrhythmia Research Foundation.

COMPLETED
Registry status
Phase 3
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

This study aims to assess whether a combined technique of substrate ablation and ablation of the clinically presenting VT at the site of early activation is superior to ablation of the clinically presenting VT alone, in enhancing long-term success of VT ablation.

Conditions Studied

Interventions

  • PROCEDURE Radiofrequency Catheter Ablation (RFCA)

Study Locations (1)

Texas

  • St.David's Medical Center - Austin

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2010-01
Est. Completion 2014-07
Phase Phase 3

What the Registry Record Tells You About NCT01045668

The ClinicalTrials.gov registry entry for NCT01045668 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 28 other Ventricular Tachycardia trials with a reported enrollment target (58% lower). The listed sponsor is Texas Cardiac Arrhythmia Research Foundation, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ventricular Tachycardia appearing as the primary indexed condition, and to 1 intervention - of which Radiofrequency Catheter Ablation (RFCA) is the first listed.

NCT01045668 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01045668 about?

NCT01045668 is a clinical study titled "Ablation of Clinical Ventricular Tachycardia Versus Addition of Substrate Ablation on the Long Term Success Rate of VT Ablation". This study aims to assess whether a combined technique of substrate ablation and ablation of the clinically presenting VT at the site of early activation is superior to ablation of the clinically presenting VT alone, in enhancing long-term success of VT ablation.

What is the current status of trial NCT01045668?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2010-01. Estimated completion is 2014-07.

What conditions does trial NCT01045668 study?

This clinical trial studies the following conditions: Ventricular Tachycardia.

What interventions are being tested in trial NCT01045668?

The interventions under investigation include: Radiofrequency Catheter Ablation (RFCA) (PROCEDURE).

Who is sponsoring clinical trial NCT01045668?

This trial is sponsored by Texas Cardiac Arrhythmia Research Foundation, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01045668 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ventricular Tachycardia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.